The UK House of Lords Science and Technology Committee has published the long-awaited report (PDF) from its inquiry into genomic medicine.
Mark Henderson at The Times has been busy today, putting out three excellent pieces on the report: a summary of the major implications
, an opinion piece
pushing the need for the health service to respond quickly to the arrival of genomic medicine, and a lengthy blog post
praising the report and providing his views in more detail.
I find little to disagree with in Henderson’s coverage, and certainly agree with his overall opinion of the report: this report is a careful, balanced analysis of the major issues facing health systems as they move into the era of genomic medicine. Since most of the problems the UK is facing in coping with this transition will also be issues for other developed countries, governments and health agencies around the world would be well-served by printing out a copy of this report and taking its major messages seriously.
I’d recommend reading all three of Henderson’s pieces for the broader context of the report (and particularly for the implications for health services). Here I want to focus on the report’s implications for the area closest to my interests: the direct-to-consumer genetic testing industry.
My position on the regulation of the direct-to-consumer genetic testing industry is pretty simple – good regulation of the industry would:
- Ensure that companies provide high-quality genetic data to consumers, along with simple and accurate descriptions of the predictive value of the tests performed;
- Ensure that information about testing companies is placed in public databases that allow consumers to make a thoroughly informed choice between genetic testing providers; and
- Not prevent customers from gaining free access to any part of their own genetic information if they want it, or position clinicians as the absolute gate-keepers to such information.
Based on what I’ve seen so far, the committee’s recommendations are a step in the right direction for point 1 and 2, and don’t seem to violate 3, so I’m reasonably happy with this section of the report.
The inquiry heard from a number of quite eminent witnesses who provided both positive and negative views on the genetic testing industry – sometimes from the same person. For instance Ron Zimmern, Executive Director of the PHG Foundation, described DTC genetic testing as providing “totally useless information”, but also argued “that companies should not be prevented from selling DCTs and … that he could ‘see nothing in a free society to suggest that we should stop people from knowing that they have a two per cent higher risk of asthma or a four per cent lower risk of heart disease”.’
Professor Peter Donnelly, who led the massive Wellcome Trust Case Control Consortium study of the genetics of common diseases, was more unambiguous in his support for the DTC industry:
Donnelly … spoke positively about DCTs and suggested that they might be the best way to ensure that technology develops to a point where it becomes useful for public healthcare. They would also be beneficial for the small number of individuals who had a high risk of developing a disease due to the additive effects of having several low risk gene markers. He thought that DCTs were the first step to a service that would eventually be incorporated into routine clinical practice.
In the Appendix of the report is a lengthy description of Donnelly’s presentation to the inquiry, where this argument is elaborated:
While most individuals would have an average risk for most diseases almost
everyone would be at very high risk for some diseases. Professor Donnelly
estimated that 95 percent of people would be in the top five percent of genetic risk
for at least one disease, 40 percent of people would be in the top one percent of
genetic risk for at least one disease and five percent of people would be in the top
0.1 percent of genetic risk for at least one disease.
[…] It may therefore be useful to think of genomic tests, including
those sold “direct to consumers”, as a tool for individuals to identify the diseases
for which they had the highest genetic risk, based on current knowledge.
Although the inquiry also heard from critics of DTC genetic testing (such as the notorious skeptic Helen Wallace of GeneWatch UK
, who predictably called for a ban on all DTC genetic tests), the more balanced view of experts such as Donnelly led the panel to make two fairly reasonable recommendations regarding regulation of the nascent DTC testing field:
- The development of a voluntary code of practice for DTC genetic testing companies, including a requirement for companies to place information about their laboratory accreditation and testing standards in the public domain, and guidance regarding the provision of pre- and post-test counselling;
- The creation of an online registry hosted by the Department of Health that lists this information about DTC genetic testing companies, and also describes “the extent to which the DNA sequence variants used … have been validated in genome-wide association studies, and shown in prospective trials to have utility for predictive genetic testing.”
Which is almost exactly what I hope to see in terms of regulation of this field. The only area I disagree is in the voluntary nature of the code of conduct, but there’s also a third recommendation that may provide heftier regulation of industry standards: the report proposes that all genetic tests, including those provided direct-to-consumer, should be reclassified from “low risk” to “medium risk”
within the current EU In Vitro Diagnostic Medical Devices Directive
. That reclassification would seem to carry with it some non-trivial paperwork for genetic testing companies to justify their tests (see the hideous flow-charts at the bottom of these pages
), but I’m currently unsure exactly how onerous this procedure is.
Hopefully this re-classification treads the fine line of protecting customers from outright scammers while not hindering legitimate genetic test providers with unnecessary bureaucracy – I’d invite anyone with a solid understanding of the Medical Devices Directive (which I completely lack) to add their thoughts in the comments.
A final thought: I may have missed it, but there seems to have been little attention paid in the report to the potential overlap between disease gene testing and more “recreational” services such as the immensely popular genetic genealogy industry. Companies often offer both of these services simultaneously (e.g. 23andMe
), but even “pure” ancestry testing carries a risk: genetic variants that appear to be perfectly benign ancestry markers today may turn out to be associated with disease at some point in the future (a probability that rises proportionately with the number of markers tested). In addition, ancestry tests do carry the risk of discovering potentially emotionally unsettling findings such as non-paternity; and a false revelation of non-paternity is potentially far more harmful than a false revelation of a 15% increased risk of psoriasis.
Does that mean that ancestry testing should be regulated just as stringently as directly disease-relevant genetic testing? Under the wording of the report (which seems to treat “genetic testing” as a monolithic entity) that would probably be the case; and perhaps that’s not such a bad thing. Apart from the dangers quoted above (which are admittedly unlikely to affect the vast majority of genetic genealogists), I’d argue that providing basic information about the laboratory validity of genetic genealogy tests and their accuracy in determining patterns of relationship or deep geographical ancestry is not an unfair hurdle for testing companies.
Anyway, I think this report should at the very least stimulate some constructive discussion about the future of the DTC genetic testing industry; whether it actually leads to the appropriate regulatory changes is, of course, another matter entirely.